16.02.2018 – 07:12

BB Biotech AG

DGAP-News: BB Biotech AG publishes its 2017 annual report

DGAP-News: BB BIOTECH AG / Key word(s): Final Results
BB Biotech AG publishes its 2017 annual report (news with additional features)

16.02.2018 / 07:00
The issuer is solely responsible for the content of this announcement.

--------------------------------------------------------------------------------
Media release as of February 16, 2018
 

Annual report of BB Biotech AG as of December 31, 2017

BB Biotech AG publishes its 2017 annual report
 

BB Biotech AG published its annual report for fiscal year 2017 today. Besides
the audited consolidated financial statements, the annual report contains
detailed information on the biotechnology sector, BB Biotech's positioning, the
therapeutic areas covered by its portfolio and the companies it is invested in.

For 2017, BB Biotech's total share return of 23.1% in CHF and 13.1% in EUR was
built on the strong portfolio performance. Strengthening of the EUR over the USD
was a major headwind for EUR denominated performance. The portfolio Net Asset
Value (NAV) increased by 23.4% in CHF, 12.5% in EUR and 29.2% in USD in the same
period, outperforming its benchmark Nasdaq Biotechnology Index by 7.5%.
Consolidated and audited full year 2017 data showed a net gain of CHF 688 mn
compared to a net loss of CHF 802 mn in the previous period.

As already announced on January 19, 2018, BB Biotech will propose an ordinary
dividend of CHF 3.30 per share at the upcoming Annual General Meeting, which
represents a yield of 5% based on the volume-weighted average price of BB
Biotech shares in December 2017. This marks a continuation of the dividend
policy as introduced in 2013.

BB Biotech's annual report 2017 can be downloaded atwww.bbbiotech.com.
 

For further information:

Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel.
+41 44 267 67 00
Dr. Silvia Schanz,ssc@bellevue.ch
Maria-Grazia Iten-Alderuccio,mga@bellevue.ch
Claude Mikkelsen,cmi@bellevue.ch

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel.
+41 44 267 67 00
Tanja Chicherio,tch@bellevue.ch

TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, tel. +41
79 423 22 28
Thomas Egger,teg@te-communications.ch
www.bbbiotech.com
 

Company profile
BB Biotech invests in companies in the fast-growing market of biotechnology and
is one of the world's largest investors in this sector. BB Biotech is listed in
Switzerland, Germany and Italy. Its investments are focused on listed companies
that are developing and commercializing novel medical treatments and cures. BB
Biotech's investment selection process is guided by the fundamental research and
analysis of physicians and molecular biologists. Its Board of Directors has many
years of experience in industry and science.

Disclaimer
This release contains forward-looking statements and expectations as well as
assessments, beliefs and assumptions. Such statements are based on the current
expectations of BB Biotech, its directors and officers, and are, therefore,
subject to risks and uncertainties that may change over time. As actual
developments may significantly differ, BB Biotech and its directors and officers
accept no responsibility in that regard. All forward-looking statements included
in this release are made only as of the date of this release and BB Biotech and
its directors and officers assume no obligation to update any forward-looking
statements as a result of new information, future events or other factors.
--------------------------------------------------------------------------------
Additional features:

Document:http://n.eqs.com/c/fncls.ssp?u=VKBPREQPXY
Document title: Media release

--------------------------------------------------------------------------------
16.02.2018  Dissemination of a Corporate News, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
--------------------------------------------------------------------------------

Language: English

Company:  BB BIOTECH AG

          Schwertstrasse 6

          8200 Schaffhausen

          Switzerland

Phone:    +41 52 624 08 45

E-mail:    info@bbbiotech.com

Internet: www.bbbiotech.ch

ISIN:     CH0038389992

WKN:      A0NFN3

Listed:   Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial
Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX



 

End of News DGAP News Service

--------------------------------------------------------------------------------

654741  16.02.2018